Overview

99Tc-MDP for Thyroid-Associated Ophthalmopathy

Status:
Completed

Trial end date:
2019-03-31

Target enrollment:

Participant gender:

Summary

To investigate the efficacy，safety and tolerability of 99Tc-MDP in comparison to Methylprednisolone, in the treatment of participants suffering from active moderate to severe TAO.

Phase:

Phase 4

Details

Lead Sponsor:

Dalian University

Treatments:

Methylene diphosphonate
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Technetium Tc 99m Medronate